Zacks Investment Research Lowers Genmab A/S (OTCMKTS:GNMSF) to Hold

Zacks Investment Research cut shares of Genmab A/S (OTCMKTS:GNMSF) from a buy rating to a hold rating in a research note issued to investors on Wednesday, reports.

According to Zacks, “Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company’s product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark. “

OTCMKTS GNMSF opened at $201.95 on Wednesday. Genmab A/S has a 52 week low of $119.10 and a 52 week high of $205.74. The stock has a market cap of $12.38 billion, a price-to-earnings ratio of 60.75 and a beta of 0.17. The company has a 50-day moving average price of $184.31 and a two-hundred day moving average price of $172.70.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Further Reading: What is a balanced fund?

Get a free copy of the Zacks research report on Genmab A/S (GNMSF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with's FREE daily email newsletter.